Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Gastrointestinal 1

Conditions

Stomach Neoplasms 1Melanoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × BO-112 × Clear all
NCT06422936 2026-01-26

SPOTLIGHT204

Highlight Therapeutics

Phase 2 Active not recruiting
60 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT04570332 2025-11-26

SPOTLIGHT203

Highlight Therapeutics

Phase 2 Completed
42 enrolled 12 charts
Dermatologic

Melanoma

NCT04508140 2024-11-29

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

Highlight Therapeutics

Phase 2 Terminated
18 enrolled 13 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡